Anteris Technologies Ltd (ASX:AVR, OTC:AMEUF) has completed treatment for the second cohort of an ongoing first-in-human study assessing the efficacy of its’ DurAVR™ transcatheter heart valve (THV) system.
The DurAVR™ aortic replacement valve is designed to address the unmet challenges faced by patients with aortic stenosis, improving their longevity and quality of life by providing a solution with the durability to last the remainder of the patient’s life.
The study is being overseen by chief medical officer Dr Chris Meduri, including the first five aortic stenosis patients implanted with DurAVR in November at the Tbilisi Heart and Vascular Clinic.
Read: Anteris Technologies buoyed by follow-up milestone from first-in-human DurAVR™ heart valve study
Australian physician Dr Karl Poon became the first Australian doctor to perform an implant surgery with DurAVR.
“Thrilled with ongoing progress”
“We are thrilled with the ongoing progress and the veracity of the results so far. The whole team including the treating physicians are excited by the results so far,” Anteris CEO Wayne Paterson said.
“The company continues to progress its clinical program and I look forward to updating the market in the near future.”
Data from this latest cohort will be review at the 30-day follow-up mark, the key inflexion point for indicating ongoing valve performance.
Anteris said all patients enrolled in the study had done exceptionally well.